NellOne Therapeutics Inc. believes it can help patients restore muscle mass and function thanks to a gene called Nell-1. If early studies bear out, the company’s research could yield protein therapeutics capable of regenerating muscle around joint replacements and even in hearts damaged by heart attacks. An in vitro study of heart muscle cells showed the protein could protect those cells and prevent them from dying in the very kind of low-oxygen situation that typifi es the conditions that heart muscle cells encounter during a heart attack. NellOne has chosen to develop its technology as a wound-healing therapy initially, because that research is farthest along and the path to market is shorter than for a cardiovascular indication.
10702 Murdock Road
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
Sales of the company’s approved cancer therapies were weaker or down, but Trodelvy is likely to see a label expansion and cell therapies are making progress.
BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.
The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.
The company posted positive initial results from the Heart-2 trial in HeFH and CAD, with strong LDL cholesterol lowering and a clean safety profile.
The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.
Adstiladrin sales hit €70m in first full year on the market
